Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00187278
Other study ID # CR03006HF
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2003
Est. completion date October 2014

Study information

Verified date January 2021
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of the study is to evaluate if patients with a standard indication for permanent ventricular pacing, left ventricular ejection fraction without limit, or any QRS duration will profit from the prevention of ventricular desynchronisation.


Description:

The study will be performed as a controlled, single-blind, international, multicenter, prospective, randomized, parallel group design. In order to pragmatically examine the effectiveness of biventricular pacing in patients with an indication for ventricular pacing, the study group with biventricular pacing is compared to a control group with standard pacemakers which only allow univentricular (right ventricular) stimulation, as it has been the standard outside of clinical studies until so far.


Recruitment information / eligibility

Status Completed
Enrollment 1833
Est. completion date October 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Presence of an indication for ventricular pacing according to the actual guidelines for the implantation of cardiac pacemakers and a need for frequent (or even permanent) ventricular pacing for: 1. Permanent 3rd degree atrioventricular (AV)-block or 2. Intermittent 3rd degree AV-block in combination with 1st degree AV-block with a pQ-interval = 220 ms or 3. 2nd degree AV-block type Mobitz II in combination with 1st degree AV-block with a pQ-interval = 220 ms or 4. 2nd degree AV-block type Mobitz I (if indicated) in combination with 1st degree AV-block with a pQ-interval = 220 ms or 5. 1st degree AV-block with a pQ-interval = 220 ms and indication for ventricular pacing (includes indication for ventricular pacing based on long HV interval measured during invasive electrophysiological testing) or 6. Sick-sinus-syndrome with symptomatic sinus bradycardia or sinus arrest as primary indication for device implantation in combination with long 1st degree AV-block with a pQ-interval = 220 ms or 7. Chronic (permanent) atrial fibrillation (flutter or tachycardia) with a spontaneous heart (ventricular) rate at rest = 60/min or 8. Chronic (permanent) atrial fibrillation (flutter or tachycardia) with a spontaneous heart (ventricular) rate at rest = 75/min, if initiation or increase of pharmacological treatment with a relevant heart rate lowering effect (negative chronotropic effect) is planned for the time after pacemaker implantation (i.e. ß-blockers for heart failure and rate control) 9. Patients scheduled for AV node ablation 2. Any QRS duration and morphology 3. Left ventricular ejection fraction (LVEF) without limit as measured by echocardiography (in at least one plane, either 4- or 2-chamber or apical long axis view) 4. Signed written informed consent of the patient or a first-degree relative for study participation after informing the patient/relative about the risks and the aim of the study 5. Willingness and ability to comply with the prescribed follow-up tests and schedule of evaluations. 6. Absence of an implanted ventricular pacing device (patients with atrial pacemakers and new need for ventricular pacing may be included) Exclusion Criteria: 1. Implanted Cardioverter Defibrillator or consideration for implantation of an ICD due to arrhythmia indication. However, ICD implant for primary prevention of sudden cardiac death in patients with LVEF = 35 % (in accordance with the actual guidelines for the implantation of arrhythmia devices[LVEF < 30%] and in accordance with the results of the SCD-Heft study [LVEF < 35%) will be allowed. 2. Implanted ventricular pacing device 3. Status 1 for cardiac transplantation and likelihood to receive transplantation within 2 years (these patients would not be expected to fulfill the follow-up requirements as outlined in this protocol) 4. Evidence of acute left ventricular dysfunction and high probability for its reversibility (e.g. acute myocarditis, tachycardiomyopathy) 5. Implanted prosthetic tricuspid valve 6. Severe musculoskeletal disorder(s) 7. Age below 18 years 8. Current or planned pregnancy in the next 6 months 9. Current or recent (within the past 30 days) participation in any other clinical investigation 10. Life expectancy of less than 6 months 11. Patient's inability to independently comprehend and complete the Quality of Life (QoL) questionnaire

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Biventricular Pacing
Biventricular Pacemaker implant
RV Pacing
Standard Pacemaker implant

Locations

Country Name City State
Germany Klinikum der Philipps-Universität Marburg Marburg

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Funck RC, Blanc JJ, Mueller HH, Schade-Brittinger C, Bailleul C, Maisch B; BioPace Study Group. Biventricular stimulation to prevent cardiac desynchronization: rationale, design, and endpoints of the 'Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)' study. Europace. 2006 Aug;8(8):629-35. — View Citation

Funck RC, Mueller HH, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg M, Wuensch D, Blanc JJ; BioPace study group. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2014 Mar;16(3):354-62. doi: 10.1093/europace/eut343. Epub 2013 Nov 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Total Mortality Number of deaths observed Study duration (5.7 years mean follow-up)
Primary Death or Heart Failure Hospitalization Number of subjects who experienced death or hospitalization where heart failure is a primary cause of hospitalization Study duration (5.7 years mean follow-up)
Secondary Death Due to Cardiovascular Causes Number of subjects who died due to cardiovascular causes, as classified by the independent Event Adjudication Committee (IEAC) Study duration (5.7 years mean follow-up)
Secondary Functional Capacity as Measured by the Distance Covered in the 6-minute Walk Test 12 months post-implant
Secondary Health Related Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire© Minnesota Living with Heart Failure (MLWHF) questionnaire score at 12 months
MLWHF score: the total scale is from 0 to 105, with higher scores indicating worse health status.
12 months post-implant
Secondary Incidence of Hospitalizations for Deterioration of Heart Failure Study duration (5.7 years mean follow-up)
Secondary Incidence of Hospitalizations for Cardiovascular Events Study duration (5.7 years mean follow-up)
Secondary Incidence of Hospitalizations for Any Reason Study duration (5.7 years mean follow-up)
Secondary Cardiac Structure and Function 12 & 24 months
Secondary Successful Implantation of the Left Ventricular Lead Implantation
Secondary Chronic Atrial Fibrillation (Defined as Presence of Atrial Fibrillation in Two Subsequent ECG´s/Visits) Chronic atrial fibrillation is defined as presence of atrial fibrillation in two subsequent ECG´s/visits. Study duration (5.7 years mean follow-up)
Secondary Functional Capacity as Measured by the Distance Covered in the 6-minute Walk Test 24 months post-implant
Secondary Health Related Quality of Life Measured by the Minnesota Living With Heart Failure Questionnaire© Minnesota Living with Heart Failure (MLWHF) questionnaire score at 24 months.
MLWHF score: the total scale is from 0 to 105, with higher scores indicating worse health status.
24 months post-implant
Secondary Duration of Hospitalizations for Deterioration of Heart Failure Study Duration (5.7 years mean follow-up)
Secondary Duration of Hospitalizations for Cardiovascular Events Study Duration (5.7 years mean follow-up)
Secondary Duration of Hospitalizations for Any Reason Study duration (5.7 years mean follow-up)
Secondary Adverse Events Related to Left Ventricular Lead Only serious adverse events related to the left ventricular lead are included. Study Duration (5.7 years mean follow-up)
See also
  Status Clinical Trial Phase
Completed NCT03799133 - Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery N/A
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01673230 - Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%) N/A
Completed NCT00982397 - Safety and Clinical Performance of the Protecta ICD and CRT-D N/A
Completed NCT00187252 - Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy N/A
Recruiting NCT04848844 - The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT02644850 - Comparison of Gated Blood-pool SPECT and Echocardiogram for Ventricular Function N/A
Terminated NCT00524862 - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death N/A
Completed NCT00526162 - ConsultaTM CRT-D Clinical Evaluation Study N/A
Withdrawn NCT00166010 - Effects of Nesiritide in Pediatric Patients With Heart Failure N/A
Completed NCT00370643 - Glucose Control in Open Heart Surgery Phase 1
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Enrolling by invitation NCT03701997 - Registry to Monitor Berlin Heart EXCOR® Pediatric VAD as a Bridge to Cardiac Transplantation.
Completed NCT02497950 - HeartMate 3 ELEVATE™ Registry
Recruiting NCT05934071 - Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.
Recruiting NCT02816047 - Austrian Wearable Cardioverter Defibrillator Registry
Completed NCT04634708 - The Use of the EXCOR Active Driving Unit for Mobilization of Pediatric Patients With Ventricular Assist Device Support
Terminated NCT02820441 - Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance Phase 4
Completed NCT00893360 - CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction Phase 1